Skip to main content

Advertisement

A population-based survey of the epidemiology of symptom-defined gastroesophageal reflux disease: the Systematic Investigation of Gastrointestinal Diseases in China

BMC Gastroenterology volume 10, Article number: 94 (2010) | Download Citation

Article metrics

Abstract

Background

The epidemiology of gastroesophageal reflux disease (GERD) has yet to be investigated using the symptomatic threshold criteria recommended by the Montreal Definition. This study aimed to determine the prevalence of symptom-defined GERD across five regions of China, and to investigate variables associated with GERD.

Methods

A representative sample of 18 000 adults (aged 18-80 years) were selected equally from rural and urban areas in each region (n = 1800). According to the Montreal Definition, GERD is present when mild symptoms of heartburn and/or regurgitation occur on ≥2 days a week, or moderate-to-severe symptoms of heartburn and/or regurgitation occur on ≥1 day a week.

Results

In total, 16 091 participants completed the survey (response rate: 89.4%) and 16 078 responses were suitable for analysis. Applying the Montreal criteria, the prevalence of symptom-defined GERD was 3.1% and varied significantly (p < 0.001) among the five regions (from 1.7% in Guangzhou to 5.1% in Wuhan) and between rural and urban populations (3.8% vs 2.4%). Factors significantly associated with GERD included living in a rural area and a family history of gastrointestinal diseases.

Conclusions

This population-based survey found that the prevalence of symptom-defined GERD in China was 3.1%, which is lower than that found in Western countries.

Open Peer Review reports

Background

Gastroesophageal reflux disease (GERD) is a chronic disease that is associated with a range of troublesome symptoms, which can in turn have a significant impact on health-related quality of life and work productivity [1–4]. It is also associated with esophageal complications such as reflux esophagitis and Barrett's esophagus [1].

Interest in the epidemiology of GERD has grown during the past few decades, but interpretation of epidemiological studies of GERD has often been hampered by the use of inconsistent symptom-based definitions of the disease [5]. In 2005, Dent and colleagues performed a systematic review of studies that defined GERD as symptoms of heartburn and/or regurgitation occurring on at least 1 day per week [5]. They concluded that the prevalence of GERD was 10-20% in Western countries and approximately 5% in Asia based on this definition.

Since then, a global evidence-based consensus (the Montreal Definition of GERD) has recommended that in population-based surveys GERD should be defined as symptoms of heartburn and/or regurgitation that are either mild and occur on at least 2 days a week, or moderate-to-severe and occur on at least 1 day a week [1]. This was considered to be the level at which these characteristic GERD symptoms become troublesome. The epidemiology of symptom-defined GERD has yet to be investigated using these threshold criteria.

We have previously validated a survey methodology for the epidemiological study of GERD in Shanghai, China [6–8]. Here, we report results from the Systematic Investigation of Gastrointestinal Diseases in China (SILC), which is a large epidemiological survey of five regions of China [9]. The aim of the SILC study was to use the symptom threshold recommended for epidemiological studies by the Montreal Definition to determine the prevalence of symptom-defined GERD across five regions of China, and to investigate variables associated with this disease.

Methods

Setting, sampling and study design

The major population centres of Shanghai, Beijing, Xi'an, Wuhan and Guangzhou (including the rural districts surrounding the cities) were selected for sampling in this study. The demographic characteristics of these areas are summarized in Table 1. Fieldwork was carried out from April 2007 to January 2008.

Table 1 Demographic characteristics of the population centres included in the study.
Full size table

As previously described [9], 18 000 residents of China aged 18-80 years were selected randomly using a stratified, multi-stage sampling methodology. Urban and rural populations, which have distinct socioeconomic characteristics (Additional File 1), were sampled in a ratio of 1:1 (n = 1800 from each stratum in each region) in proportion to the overall age and sex distribution of each region.

All respondents completed a survey consisting of a general information questionnaire and a Chinese version of the Reflux Disease Questionnaire (RDQ) [7]. A random sub-sample of 20% of the respondents in each region was asked to undergo a physical examination that included measurement of weight, height, and waist and hip circumference. The residents of Shanghai were also invited to undergo endoscopy, the results of which are described elsewhere [10, 11].

The general information questionnaire collected self-reported information on age, height, weight, sex, marital status, education, income, occupation, lifestyle habits, health status, family history of gastrointestinal diseases, and medical history (current and previous medical problems and related treatment).

The RDQ was used to determine the frequency and severity of heartburn (defined as 'burning behind the breastbone' and/or 'pain behind the breastbone') and regurgitation (defined as 'acid taste in the mouth' and/or 'unpleasant movement of materials upwards from the stomach') during a 1-month recall period. The frequency and severity of each RDQ item are scored on a 6-point Likert scale (0-5; where 0 is no symptoms, 1 is symptoms on less than 1 day a week or very mild symptoms, and 5 is daily or severe symptoms) (Additional File 2). The validity and reliability of the RDQ as a diagnostic tool has been previously demonstrated [12]. The Chinese version of the RDQ used in the present study underwent extensive linguistic validation including forward and backward translation, cognitive debriefing of patients with GERD, and expert input from gastroenterologists. The pilot study showed that a version with a 1-week recall period had credible reliability and construct validity [7]. Applying the Montreal Definition, symptom-defined GERD was defined as mild symptoms of heartburn and/or regurgitation occurring on at least 2 days a week (a frequency score ≥3 and a severity score of ≥2 for any of the relevant symptoms), or moderate-to-severe symptoms of heartburn and/or regurgitation occurring on at least 1 day a week (a frequency score ≥2 and a severity score ≥3 for any of the relevant symptoms).

Participants filled out the questionnaires themselves, either in local residential committee offices or in their own home, with trained and supervised facilitators available to explain any questions that were unclear. Informed consent was obtained, and individuals were free to discontinue their participation in the study at any time. The study was approved by the Ethics Committee of the Second Military Medical University, Shanghai, China.

Data collection and analysis

Data were collected and validated as previously described, with the SAS 9.1.3 program (SAS Institute, Cary, NC, USA) used to complete data analyses [9]. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by univariate and multivariate logistic regression in order to examine factors that are potentially associated with symptom-defined GERD. The Cochran-Armitage test was used for trend testing and the Cochran-Mantel-Haenszel test was used to compare the baseline characteristics of respondents in the different study centres.

Results

Response rate and sample characteristics

In total, 16 091 individuals completed the survey (a response rate of 89.4%) and 16 078 responses (99.9%) were suitable for analysis. In the 20% sub-sample, the response rate was 89.4% and 3214 responses were suitable for analysis (99.8%). The mean (SD) age of participants in the total study sample was 42.5 (15.2) years; 52.2% of participants were female. Body mass index (BMI) ranged from 11.8 kg/m2 to 41.0 kg/m2, with a mean (SD) of 22.6 kg/m2 (3.3). The majority of participants reported that they did not drink alcohol (79.7%) or smoke cigarettes (69.9%). The baseline characteristics of each study centre are detailed in Additional File 3. Approximately half of all respondents lived in the rural areas of each of the studied provinces.

Prevalence of reflux symptoms

At least monthly symptoms of heartburn and/or regurgitation were reported by 12.7% of participants (Table 2), with regurgitation (10.8%) being more prevalent than heartburn (4.0%). The prevalence estimates of individual RDQ items were as follows: 8.7% for 'an acid taste in the mouth', 5.3% for 'an unpleasant movement of material upwards from the stomach', 2.4% for 'burning behind the breastbone', and 2.8% for 'pain behind the breastbone'. Approximately 5% of participants experienced reflux symptoms on at least 1 day per week (Table 3). Regurgitation (4.2%) remained more common than heartburn in these participants (1.8%).

Table 2 Prevalence of at least monthly symptoms of heartburn or regurgitation (any frequency or severity).
Full size table
Table 3 Regional variation in the prevalence of reflux symptoms and symptom-defined gastroesophageal reflux disease (GERD).
Full size table

Most reflux symptoms were experienced less often than 1 day a week, and most were very mild in severity (Figures 1a and 1b).

Figure 1
figure1

Prevalence of reflux symptoms by (a) frequency and (b) severity (n = 16 078).

Full size image

Prevalence of GERD

The prevalence of symptom-defined GERD was 3.1% overall (2.4% in urban areas and 3.8% in rural areas), and varied among the five regions studied, from 1.7% in Guangzhou to 5.1% in Wuhan (Table 3). The prevalence of symptom-defined GERD in the 20% sub-sample was 3.4%.

A total of 326 participants (2.0%) reported that they had previously been diagnosed with GERD by a physician: 73 of these met the study criteria for symptom-defined GERD and 253 did not (Table 4). The majority of the individuals who reported a history of GERD had been prescribed drug therapy at some point in time (76.1%; 248/326). The mean (SD) reported age for a first physician diagnosis of GERD was 37.8 (14.1) years. For almost all participants (99.7%), this physician diagnosis was more than 5 years ago.

Table 4 Self-reported history of GERD and treatment in participants with and without symptom-defined GERD.
Full size table

Factors associated with the presence of GERD

Factors found to be associated with the presence of symptom-defined GERD in a multiple logistic regression analysis are presented in Table 5. Participants living in rural areas were more likely to have symptom-defined GERD than those living in urban areas, whereas individuals aged 18-29 years were less likely to have symptom-defined GERD than those aged 30-39 years. Symptom-defined GERD was also associated with decreasing self-reported health status and a family history of gastrointestinal disease, and was inversely associated with recreational exercise taken at least once a week. Compared with participants without GERD, those with symptom-defined GERD were more likely to consume alcohol and were less likely to have attained a secondary/high school educational level. In univariate analysis, a BMI of ≥27.5 kg/m2 was associated with a significant increase in the risk of GERD. Trend testing also showed a relationship between BMI and the occurrence of GERD (p = 0.003). However, there was no significant association between a BMI of ≥27.5 kg/m2 and GERD in the multivariate analysis. Sex, smoking, occupation and income were not significantly associated with symptom-defined GERD.

Table 5 Characteristics of participants with and without symptom-defined GERD, and their association with symptom-defined GERD.
Full size table

When separated into individuals who reported heartburn of any frequency or severity (n = 638) and those who reported regurgitation of any frequency or severity (n = 1738), a number of differences were found in the factors associated with regurgitation and heartburn. Alcohol consumption was significantly associated with the presence of regurgitation (OR: 1.34; 95% CI: 1.15-1.55) but not heartburn (OR: 1.15; 95% CI: 0.91-1.45). Conversely, a BMI of ≥27.5 kg/m2 was significantly associated with the presence of heartburn (OR: 1.47; 95% CI: 1.14-1.91) but not regurgitation (OR: 1.10; 95% CI: 0.92-1.33). Compared with participants aged 30-39 years, those aged 70-80 years had a significantly higher risk of heartburn (OR: 1.45; 95% CI: 1.02-2.07) but a significantly lower risk of regurgitation (OR: 0.70; 95% CI: 0.55-0.90). Living in a rural area, decreasing health status and a family history of gastrointestinal disease were associated with a significant increase in the risk of both heartburn and regurgitation (data not shown).

No significant associations (in univariate or multivariate analyses) were found between symptom-defined GERD and BMI or waist-to-hip ratio among the 20% sub-sample who were randomly selected to undergo a physical examination (Table 6).

Table 6 Association of symptom-defined GERD with BMI and waist-to-hip ratio in participants who underwent a physical examination (20% sub-sample, n = 3214).
Full size table

The presence of symptom-defined GERD was associated with a self-reported history of dyspepsia (OR: 2.81; 95% CI: 2.20-3.59), dysphagia (OR: 4.56; 95% CI: 2.30-9.04), gastritis (OR: 3.06; 95% CI: 2.46-3.81) or peptic ulcer disease (OR: 2.05; 95% CI: 1.52-2.76). There was no significant association between GERD and self-reported irritable bowel syndrome (OR: 0.53; 95% CI: 0.12-2.42). Self-reported joint disorders (OR: 2.03; 95% CI: 1.58-2.61) and chronic cough (OR: 2.14; 95% CI: 1.39-3.28) were associated with GERD, whereas asthma (OR: 0.87; 95% CI: 0.39-1.94), hoarseness (OR: 0.76; 95% CI: 0.38-1.55) and non-cardiac chest pain (OR: 1.54; 95% CI: 0.72-3.31) were not.

Discussion

This large multicentre study of the epidemiology of symptom-defined GERD surveyed a total population of 18 000 individuals from five regions across China. To our knowledge, it is the first epidemiological study anywhere in the world to apply the symptom-based criteria recommended by the Montreal Definition of GERD for use in population-based studies [1]. The overall prevalence of symptom-defined GERD in the present study was 3.1%. The prevalence varied widely between the regions studied, from 1.7% in Guangzhou to 5.1% in Wuhan, which emphasizes the cultural and demographic variability in this vast country and suggests that future epidemiological studies should not extrapolate findings in one area to the country as a whole.

Overall, 2% of study participants reported a pre-existing GERD diagnosis, and 76.1% of these individuals had received drug treatment for GERD, although the details of this treatment (e.g. drug name, dose and period of administration) were not recorded. Of those participants who had been diagnosed and treated for GERD, 77.0% did not reach the symptom threshold criteria for GERD used in this study, perhaps because their treatment was successful in controlling their symptoms. Conversely, 85.3% of participants who met symptom-defined GERD criteria had not been previously diagnosed with GERD. This suggests that consultation for reflux symptoms in this population is low, despite the negative impact that the symptoms are known to have on health-related quality of life [13].

The prevalence of symptom-defined GERD reported in the current study was lower than that found in the pilot study in Shanghai (6.2%) [6]. This is likely to be because the pilot study used a simple frequency threshold of reflux symptoms on at least 1 day a week to define GERD whereas the present study, in accordance with the Montreal Definition, excluded very mild symptoms of any frequency and mild symptoms on only 1 day a week from the definition of GERD.

The prevalence of GERD was comparable to or lower than that found in previous Chinese population-based surveys that used a variety of definitions of GERD (2.4-17.0%) [6, 14–20], again reflecting the conservative definition used in the SILC study. The prevalence of symptoms of heartburn and/or regurgitation on at least 1 day a week was 5.2% in the SILC study, compared with 2.5-12.9% in previous studies conducted in China [6, 14–20].

Despite the variation in the prevalence of GERD across the study centres, our results add weight to the conclusion that there is a lower prevalence of symptom-defined GERD in China (below 5%) than in Western countries (10-20%) [5]. This is mostly a result of a lower prevalence of heartburn (1.9-4.1% vs 7.7-17.8%) rather than regurgitation (5.5-7.8% vs 6.3-14.5%) in China [15, 16] compared with Western populations [21]. Heartburn has also been found to be less common than regurgitation in Iran [22] and Turkey [23]. The reason for these differences in symptom patterns is unclear. They could be a result of genetic or pathophysiological differences between Western and Asian populations, although the evidence for this is limited [21]. The term heartburn is also less well understood in China than in Western countries. However, the linguistic validation performed as part of the current study [9] should have minimized the effect of such cultural differences.

Factors associated with GERD

The factors most strongly associated with symptom-defined GERD were declining self-reported health status and a family history of gastrointestinal disease. Self-reported health status is known to be an accurate predictor of morbidity and mortality in China and other Asian populations as well as worldwide [24, 25], and the association we observed may reflect the burden of symptoms and comorbidity in individuals with GERD. An association of GERD with a relevant family history has been seen in previous studies [5, 26], and the results of twin studies in Sweden and the UK have also provided evidence of a genetic component to the disease [27–29]. In support of this genetic association, a recent study found an association between GERD and the gene encoding collagen type III alpha 1 (COL3A1) [30].

We also found that individuals living in a rural area had a higher risk of GERD than those living in an urban area. The reasons for this are unclear, and previous studies in China do not provide consistent support for this association. Pan et al. found that GERD was more common in rural than urban areas in Beijing (12.5% vs 8.6%) but that the reverse was true in Shanghai (7.0% vs 8.6%) [20]. Wang et al. found that GERD was more common in urban (21.1%) than rural (17.4%) areas of Xi'an [16].

The current study found a significant association between obesity and heartburn, but not between obesity and symptom-defined GERD; however, the pilot study using a less stringent definition of GERD did find a positive association with obesity [6]. Previous population-based studies that looked at the association of GERD with BMI in China have also reported inconsistent results [6, 14–20]. This contrasts with the increasingly clear association between GERD and obesity that has been found in Western countries, particularly in the USA [31–34]. It is possible that this reflects differences in the prevalence of other etiological factors such as hiatus hernia or perhaps the low prevalence of obesity in China.

Association of GERD with self-reported medical history

The current results support an association of GERD with a history of peptic ulcer disease [16, 35–37], but do not support associations seen in Europe between GERD and irritable bowel syndrome or asthma [36, 38, 39] or a protective effect for gastritis against GERD [40]. It is, however, important to distinguish between objectively demonstrated gastritis and the patient-reported history of gastritis that is reported in the present study. In Asian countries 'gastritis' commonly denotes upper gastrointestinal discomfort and a diagnosis is unlikely to be based on endoscopic biopsy or serum pepsinogen measurement. GERD was associated with chronic cough in our study, supporting the established association with this extraesophageal syndrome [1].

The association we found between joint disorders (rheumatoid arthritis and osteoarthritis) and GERD may reflect the use of non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief in this population [41].

Strengths and limitations

This large, population-based, epidemiological study provides high-quality data on the prevalence of GERD in five geographically diverse regions of China. Key strengths are the large sample size, the use of a validated symptom questionnaire and survey methodology, and also the use of a symptom-based definition of GERD that was built on global consensus. Importantly, the population sampling and survey administration methods achieved a high response rate (89.4%) that minimized the potential for responder bias and generated representative adult population samples [9]. In addition, by gathering data on treatment history, it was possible to gain insight into how existing treatment of GERD may affect prevalence data.

Samples sizes were equal for rural and urban populations and for each population region, and were not weighted in proportion to the actual population size. However, available data indicate that the mean ratio of urban to rural people for all five study regions was approximately 0.81:1, ranging from 0.71:1 (in Wuhan) to 0.98:1 (in Beijing) [9] and in China overall this ratio was approximately 0.82:1 in 2007 [42]. Therefore we consider the urban and rural strata in this study to be sufficiently representative of the five study regions.

Language barriers and cultural differences are inevitable study limitations, although every effort was made to overcome these through the survey administration techniques and the linguistic validation of questionnaires [9]. Another potential limitation is that the medical history of participants was self-reported, although it should be noted that it is standard practice in China for patients to keep their own medical records which may reduce the impact of this limitation.

Further study

Further investigation into potential risk factors and comorbidities associated with GERD is warranted, ideally in relation to incident cases of GERD. Ascertaining details of the drug treatments used by participants for diagnosed conditions would be of value in future studies, particularly use of NSAIDs, acetylsalicylic acid, traditional herbal remedies and treatments for GERD. Further research is needed to clarify whether the prevalence of GERD is increasing in China, and the factors that may be associated with such an increase.

Conclusions

This study suggests that the prevalence of symptom-defined GERD is lower in China than in Western countries. This is mostly a result of a lower prevalence of heartburn rather than regurgitation in China compared with Western populations. The prevalence of symptom-defined GERD varies widely across China, which argues that future studies should not extrapolate findings in one area to the country as a whole.

References

  1. 1.

    Vakil N, Veldhuyzen van Zanten S, Kahrilas P, Dent J, Jones R: The Montreal definition and classification of gastro-esophageal reflux disease (GERD) - a global evidence-based consensus. Am J Gastroenterol. 2006, 101: 1900-1920. 10.1111/j.1572-0241.2006.00630.x.

  2. 2.

    Armstrong D: Systematic review: persistence and severity in gastroesophageal reflux disease. Aliment Pharmacol Ther. 2008, 28: 841-853.

  3. 3.

    Liker H, Hungin AP, Wiklund I: Management of reflux disease in primary care: the patient perspective. J Am Board Fam Pract. 2005, 18: 393-400. 10.3122/jabfm.18.5.393.

  4. 4.

    Wahlqvist P, Reilly M, Barkun AN: Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther. 2006, 24: 259-272. 10.1111/j.1365-2036.2006.02996.x.

  5. 5.

    Dent J, El-Serag HB, Wallander MA, Johansson S: Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005, 54: 710-717. 10.1136/gut.2004.051821.

  6. 6.

    Ma X, Cao Y, Wang R, Yan X, Zhao Y, Zou D, Wallander MA, Johansson S, Liu W, Gu Z, Zhao J, He J: Prevalence of, and factors associated with, gastroesophageal reflux disease: a population-based study in Shanghai, China. Dis Esophagus. 2009, 22: 317-322. 10.1111/j.1442-2050.2008.00904.x.

  7. 7.

    Cao Y, Yan X, Ma X, Wang R, Fu Z, Johansson S, Wallander M-A, He J: Validation of a survey methodology for gastroesophageal reflux disease in China. BMC Gastroenterol. 2008, 8: 37-10.1186/1471-230X-8-37.

  8. 8.

    Wang R, Yan X, Ma X-Q, Cao Y, Wallander M-A, Johansson S, He J: Burden of gastroesophageal reflux disease in Shanghai, China. Dig Liver Dis. 2009, 41: 110-115. 10.1016/j.dld.2008.06.014.

  9. 9.

    Yan X, Wang R, Zhao Y, Ma X, Fang J, Yan H, Kang X, Yin P, Hao Y, Li Q, Dent J, Sung J, Zou D, Johansson S, Halling K, Liu W, He J: Systematic investigation of gastrointestinal diseases in China (SILC): validation of survey methodology. BMC Gastroenterol. 2009, 9: 86-10.1186/1471-230X-9-86.

  10. 10.

    Li Z, Zou D, Chen J, Shi X, Gong Y, Man X, Gao L, Ma X, Zhao Y, Wang R, Yan X, Dent J, Sung JJ, Wernersson B, Johansson S, Liu W, He J: Epidemiology of peptic ulcer: the Systematic Investigation of gastrointestinaL diseases in China (SILC) study. Gastroenterology. 2009, 136 (Suppl 1): S1088-

  11. 11.

    Zou D, He J, Chen J, Gong Y, Man X, Gao L, Wang R, Zhao Y, Ma X, Yan X, Liu W, Wernersson B, Johansson S, Dent J, Sung JJ, Mastracci L, Li Z: Epidemiology of gastroesophageal reflux disease and esophagitis: the Systematic Investigation of gastrointestinaL diseases in China (SILC) study. Gastroenterology. 2009, 136 (Suppl 1): S1911-

  12. 12.

    Dent J, Vakil N, Jones R, Bytzer P, Schöning U, Halling K, Junghard O, Lind T: Accuracy of the diagnosis of GERD by physicians, questionnaire and a trial of proton pump inhibitor therapy: the Diamond Study. Gut. 2010, 59: 714-721. 10.1136/gut.2009.200063.

  13. 13.

    Wang R, Zou D, Zhao Y, Ma X, Yan X, Yan H, Fang J, Yin P, Kang X, Hao Y, Li Q, Dent J, Sung JJ, Halling K, Johansson S, Liu W, He J: The impact of gastroesophageal reflux disease on daily life: the Systematic Investigation of gastrointestinaL diseases in China (SILC) epidemiological study. Gastroenterology. 2009, 136 (Suppl 1): T1076-

  14. 14.

    Li YM, Du J, Zhang H, Yu CH: Epidemiological investigation in outpatients with symptomatic gastroesophageal reflux from the Department of Medicine in Zhejiang Province, east China. J Gastroenterol Hepatol. 2008, 23: 283-289. 10.1111/j.1440-1746.2007.05045.x.

  15. 15.

    Chen M, Xiong L, Chen H, Xu A, He L, Hu P: Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: a population-based study in South China. Scand J Gastroenterol. 2005, 40: 759-767. 10.1080/00365520510015610.

  16. 16.

    Wang JH, Luo JY, Dong L, Gong J, Tong M: Epidemiology of gastroesophageal reflux disease: a general population-based study in Xi'an of Northwest China. World J Gastroenterol. 2004, 10: 1647-1651.

  17. 17.

    Wong WM, Lai KC, Lam KF, Hui WM, Huang JQ, Xia HH, Hu WH, Lam CL, Chan CK, Lam SK, Wong BC: Onset and disappearance of reflux symptoms in a Chinese population: a 1-year follow-up study. Aliment Pharmacol Ther. 2004, 20: 803-812. 10.1111/j.1365-2036.2004.02198.x.

  18. 18.

    Wong WM, Lai KC, Lam KF, Hui WM, Hu WH, Lam CL, Xia HH, Huang JQ, Chan CK, Lam SK, Wong BC: Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther. 2003, 18: 595-604. 10.1046/j.1365-2036.2003.01737.x.

  19. 19.

    Hu WH, Wong WM, Lam CL, Lam KF, Hui WM, Lai KC, Xia HX, Lam SK, Wong BC: Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study. Aliment Pharmacol Ther. 2002, 16: 2081-2088. 10.1046/j.1365-2036.2002.01377.x.

  20. 20.

    Pan G, Xu G, Ke M, Han S, Guo H, Li Z, Fang X, Zou D, Lu S, Liu J: Epidemiological study of symptomatic gastroesophageal reflux disease in China: Beijing and Shanghai. Chin J Dig Dis. 2000, 1: 2-8. 10.1046/j.1443-9573.2000.00001.x.

  21. 21.

    Sharma P, Wani S, Romero Y, Johnson D, Hamilton F: Racial and geographic issues in gastroesophageal reflux disease. Am J Gastroenterol. 2008, 103: 2669-2680. 10.1111/j.1572-0241.2008.02089.x.

  22. 22.

    Nasseri-Moghaddam S, Mofid A, Ghotbi MH, Razjouyan H, Nouraie M, Ramard AR, Zaer-Rezaie H, Habibi R, Rafat-Zand K, Malekzadeh R: Epidemiological study of gastro-oesophageal reflux disease: reflux in spouse as a risk factor. Aliment Pharmacol Ther. 2008, 28: 144-153. 10.1111/j.1365-2036.2008.03708.x.

  23. 23.

    Bor S, Mandiracioglu A, Kitapcioglu G, Caymaz-Bor C, Gilbert RJ: Gastroesophageal reflux disease in a low-income region in Turkey. Am J Gastroenterol. 2005, 100: 759-765. 10.1111/j.1572-0241.2005.41065.x.

  24. 24.

    Idler EL, Benyamini Y: Self-rated health and mortality: a review of twenty-seven community studies. J Health Soc Behav. 1997, 38: 21-37. 10.2307/2955359.

  25. 25.

    Chandola T, Jenkinson C: Validating self-rated health in different ethnic groups. Ethn Health. 2000, 5: 151-159. 10.1080/713667451.

  26. 26.

    Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Risk factors associated with symptoms of gastroesophageal reflux. Am J Med. 1999, 106: 642-649. 10.1016/S0002-9343(99)00121-7.

  27. 27.

    Zheng Z, Nordenstedt H, Pedersen NL, Lagergren J, Ye W: Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins. Gastroenterology. 2007, 132: 87-95. 10.1053/j.gastro.2006.11.019.

  28. 28.

    Mohammed I, Cherkas LF, Riley SA, Spector TD, Trudgill NJ: Genetic influences in gastro-oesophageal reflux disease: a twin study. Gut. 2003, 52: 1085-1089. 10.1136/gut.52.8.1085.

  29. 29.

    Cameron AJ, Lagergren J, Henriksson C, Nyren O, Locke GR, Pedersen NL: Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology. 2002, 122: 55-59. 10.1053/gast.2002.30301.

  30. 30.

    Asling B, Jirholt J, Hammond P, Knutsson M, Walentinsson A, Davidson G, Agreus L, Lehmann A, Lagerstrom-Fermer M: Collagen type III alpha I is a gastro-oesophageal reflux disease susceptibility gene and a male risk factor for hiatus hernia. Gut. 2009, 58: 1063-1069. 10.1136/gut.2008.167353.

  31. 31.

    El-Serag H: Role of obesity in GORD-related disorders. Gut. 2008, 57: 281-284. 10.1136/gut.2007.127878.

  32. 32.

    El-Serag H: The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci. 2008, 53: 2307-2312. 10.1007/s10620-008-0413-9.

  33. 33.

    Hampel H, Abraham NS, El-Serag HB: Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005, 143: 199-211.

  34. 34.

    Corley DA, Kubo A: Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol. 2006, 101: 2619-2628. 10.1111/j.1572-0241.2006.00539.x.

  35. 35.

    Aro P, Storskrubb T, Ronkainen J, Bolling-Sternevald E, Engstrand L, Vieth M, Stolte M, Talley NJ, Agreus L: Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol. 2006, 163: 1025-1034. 10.1093/aje/kwj129.

  36. 36.

    Ruigómez A, García Rodríguez LA, Wallander MA, Johansson S, Graffner H, Dent J: Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther. 2004, 20: 751-760. 10.1111/j.1365-2036.2004.02169.x.

  37. 37.

    Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, Farahmand BY, Winchester CC, Roda E, Bazzoli F: Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: Loiano-Monghidoro study. Gut. 2008, 57: 1354-1359. 10.1136/gut.2007.145177.

  38. 38.

    Ruigómez A, García Rodríguez LA, Wallander MA, Johansson S, Thomas M, Price D: Gastroesophageal reflux disease and asthma: a longitudinal study in UK general practice. Chest. 2005, 128: 85-93. 10.1378/chest.128.1.85.

  39. 39.

    Ruigómez A, Wallander MA, Johansson S, García Rodríguez LA: Irritable bowel syndrome and gastroesophageal reflux disease in primary care: is there a link?. Dig Dis Sci. 2009, 54: 1079-1086. 10.1007/s10620-008-0462-0.

  40. 40.

    Voutilainen M, Sipponen P, Mecklin JP, Juhola M, Farkkila M: Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion. 2000, 61: 6-13. 10.1159/000007730.

  41. 41.

    Zhang FC: Rheumatology in China - brief introduction of the development of Chinese rheumatology. Rheumatology (Oxford). 2006, 45: 1323-1324. 10.1093/rheumatology/kel257.

  42. 42.

    China statistical yearbook. [http://www.stats.gov.cn/tjsj/ndsj/2008/indexeh.htm]

  43. 43.

    1% sample survey data held in 2005 by government in Shanghai. [http://www.stats-sh.gov.cn/english/index.htm]

  44. 44.

    Xi'an census 2000. [http://www.stats.gov.cn/tjsj/ndsj/renkoupucha/2000fenxian/htm/table2.htm]

  45. 45.

    1% sample survey data held in 2005 by government in Beijing. [http://www.bjstats.gov.cn/tjnj/2006-tjnj/content/mV11_03-11.htm]

  46. 46.

    1% sample survey data held in 2005 by government in Wuhan. [http://www.whtj.gov.cn/documents/tjnj2006/2/2-5.htm]

  47. 47.

    NBSC: 1% sample survey data held in 2005 by government in Guangdong. 2007, Beijing: National Bureau of Statistics of China

  48. 48.

    World Health Organization: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004, 363: 157-163. 10.1016/S0140-6736(03)15268-3.

Pre-publication history

  1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/10/94/prepub

Download references

Acknowledgements

We thank Dr Christopher Winchester and Dr Catherine Hill, from Oxford PharmaGenesis™ Ltd, who provided writing support funded by AstraZeneca R&D, Mölndal, Sweden.

Author information

Author notes

    Affiliations

    1. Department of Health Statistics, Second Military Medical University, Shanghai, China

      • Jia He
      • , Xiuqiang Ma
      • , Yanfang Zhao
      • , Rui Wang
      •  & Xiaoyan Yan

    2. Department of Health Statistics, Xi'an Jiao Tong University, Xi'an, China

      • Hong Yan
      •  & Qiang Li

    3. Department of Health Statistics, Huazhong Science and Technology University, Wuhan, China

      • Ping Yin

    4. Department of Health Statistics, Peking University, Beijing, China

      • Xiaoping Kang

    5. Department of Health Statistics, Zhongshan Medical University, Guangzhou, China

      • Jiqian Fang
      •  & Yuantao Hao

    6. Department of Gastroenterology, Hepatology & General Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia

      • John Dent

    7. Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, China

      • Joseph JY Sung

    8. Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai, China

      • Duowu Zou
      •  & Zhaoshen Li

    9. AstraZeneca R&D Mölndal, Sweden

      • Saga Johansson

    10. Department of Public Health and Caring Sciences, Uppsala University, Sweden

      • Mari-Ann Wallander

    11. Previous Address: R&D Medical Affairs, AstraZeneca Pharmaceutical Company Limited, Shanghai, China

      • Wenbin Liu

    12. Previous Address: AstraZeneca R&D Mölndal, Sweden

      • Mari-Ann Wallander

    Authors

    1. Search for Jia He in:

    2. Search for Xiuqiang Ma in:

    3. Search for Yanfang Zhao in:

    4. Search for Rui Wang in:

    5. Search for Xiaoyan Yan in:

    6. Search for Hong Yan in:

    7. Search for Ping Yin in:

    8. Search for Xiaoping Kang in:

    9. Search for Jiqian Fang in:

    10. Search for Yuantao Hao in:

    11. Search for Qiang Li in:

    12. Search for John Dent in:

    13. Search for Joseph JY Sung in:

    14. Search for Duowu Zou in:

    15. Search for Mari-Ann Wallander in:

    16. Search for Saga Johansson in:

    17. Search for Wenbin Liu in:

    18. Search for Zhaoshen Li in:

    Corresponding author

    Correspondence to Zhaoshen Li.

    Additional information

    Competing interests

    X. Yan, R. Wang, Y. Zhao, X. Ma, D. Zou, Z. Li, H. Yan, P. Yin, X. Kang, J. Fang, Y. Hao, and Q. Li declare that they have no competing interests. J. He has served as the Director of the Department of Health Statistics, Second Military Medical University and has received research funding from AstraZeneca. J. Dent has served as a speaker, a consultant and an advisory board member for AstraZeneca, and has received research funding from AstraZeneca. J.J.Y. Sung has served as a speaker, a consultant and an advisory board member for AstraZeneca, and has received research funding from AstraZeneca. S. Johansson is an employee of AstraZeneca. W. Liu and M-A. Wallander were employees of AstraZeneca at the time the study was conducted. W. Liu is now employed by Genzyme and M-A. Wallander is now employed by Bayer Healthcare. The study was funded by AstraZeneca R&D, Mölndal, Sweden. AstraZeneca had no role to play in the content and conduct of the study.

    Authors' contributions

    JH, XM, YZ, RW, XY, JD, JJYS, DZ, M-AW, SJ, WL and ZL made substantial contributions to the conception and design of the study. JH, XM, YZ, RW, XY, HY, PY, XK, JF, YH, QL, WL and ZL participated in data collection. JH, XM, YZ, RW, XY, JD, JJYS, DZ, M-AW, SJ and ZL analyzed and interpreted the data. All authors have been involved in critically revising the manuscript for intellectual content, and have given final approval of the version to be published.

    Jia He, Xiuqiang Ma, Yanfang Zhao contributed equally to this work.

    Electronic supplementary material

    Authors’ original submitted files for images

    Below are the links to the authors’ original submitted files for images.

    Authors’ original file for figure 1

    Rights and permissions

    Reprints and Permissions

    About this article

    Keywords

    • Irritable Bowel Syndrome
    • Peptic Ulcer Disease
    • Gastroesophageal Reflux Disease
    • Gastrointestinal Disease
    • Reflux Symptom

    BMC Gastroenterology

    ISSN: 1471-230X

    Contact us